Healthcare Sector

Dr Lal PathLabs is focusing on innovation, including new wellness packages and high-end, super-speciality tests, with a focus on capturing prescription shares

The surge has come alongside a decline in average issue sizes and more muted listing-day returns compared with last year

Financial services accounted for the largest share of IPO issuance in 2025, reflecting strong issuance from NBFCs, asset managers, insurers and financial platforms during the year

JM Financial has set a target price of ₹1,093 on Fortis Healthcare stock, a potential upside of 22.7 per cent from Friday's closing price

The three-day subscription window to bid for the Gujarat Kidney IPO will close on Wednesday, December 24, 2025

Gujarat Kidney IPO will be offered at a price band of ₹108 to ₹114 per share, with a lot size of 128 shares

The US remains the world's most lucrative outsourcing market, with healthcare spending touching nearly $5 trillion in CY24, accounting for 17-18 per cent of GDP.

Industry says earmarking funds for public health at par with national security will help channel revenue for public health infra

Thyrocare Technologies board had fixed November 28 as the record date for its 2:1 bonus share issue. This smallcap stock has gained 40 per cent in the last two months.

Dr Reddy's Laboratories on Monday said partnerships between policymakers and industry are vital to build a future-ready healthcare system that serves millions. Satish Reddy, the chairman of the Hyderabad-based drug major, joined industry leaders at the sixth Pre-Budget Consultation chaired by Union Finance Minister Nirmala Sitharaman in the national capital. He shared his perspective on the importance of risk-based innovation funding to strengthen India's pharmaceutical ecosystem and accelerate breakthroughs that improve patient access and affordability. "At Dr Reddy's, we believe that partnerships between policymakers and industry are vital to building a future-ready healthcare system that serves millions," Reddy said in a post shared by the drug firm on social networking platform LinkedIn.

JM Financial upgraded the stock to an 'Add' rating after the company reported a 74 per cent jump in its September quarter net profit

The deal marks the Indian hospital chain's entry into the British healthcare market, strengthening its ambition to expand globally

Amid growing demand for stricter compliance with safety and quality control norms for medical products, the Centre is framing a law to strengthen the legal framework for drug quality testing and market surveillance, along with regulation of medical devices and cosmetics. One of the major reasons behind the drafting of the law is the repeated complaints and concerns flagged by health regulators across the globe, including the WHO, over serious quality lapses by Indian drug manufacturers. The draft of the 'Drugs, Medical Devices and Cosmetics Act 2025', which the government aims to introduce in the upcoming Winter session of Parliament, was presented by Drugs Controller General of India (DCGI) Dr Rajeev Raghuvanshi at a high-level meeting of the Union health ministry held on Tuesday, the sources said. The meeting was chaired by Union Health Minister J P Nadda. During the meeting, senior officials from the Drugs Controller General of India (DCGI) and the Central Drugs Standard Control

The Central Board of Indirect Taxes and Customs (CBIC) recently announced that 90 per cent of GST refunds will now be released upfront for low-risk taxpayers

The regulator has sought a list of cough syrup manufacturers from all states and UTs following reports of toxic contaminants linked to child deaths in Madhya Pradesh

While such practices exist in leading private facilities, experts say public hospitals, often stretched and underfunded, struggle with outdated wiring, inadequate maintenance, and lax inspection

The CGHS rate revision could lift hospital chains' revenues and margins, say analysts. Here are the listed stocks set to benefit most from the policy update

Medicines, including some life saving drugs, and medical devices are set to become cheaper from Monday with the new GST rates kicking in, making healthcare more affordable and accessible for every citizen, according to industry players. With the landmark GST reforms announced by Prime Minister Narendra Modi come into effect from September 22, it will make healthcare more affordable and accessible for every citizen, Indian Pharmaceutical Alliance Secretary General Sudarshan Jain said. "Most medicines, earlier taxed at 12 per cent, will now attract just 5 per cent GST. In addition, 36 critical life-saving drugs for cancer, genetic and rare diseases, and cardiovascular conditions have been fully exempted," he added. The GST Council has also rationalised tax slabs on health and life insurance premiums, glucometers, and corrective spectacles, Jain said. "These measures mark a transformative shift in India's healthcare landscape, delivering direct savings to patients, easing the burden o

Tern Group secured $24 mn in Series A funding led by Notion Capital to expand nurse training, strengthen its AI talent platform, and scale healthcare placements globally

The company will widen its Bengaluru capability centre, targeting headcount growth to 400 from 250 by end-2025